Holen Sie sich die Stockscreener-App
514.20
2.39%
-12.60
Handel nachbörslich:
508.00
-6.20
-1.21%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TMO?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$526.80
Offen:
$525.18
24-Stunden-Volumen:
1.80M
Relative Volume:
0.97
Marktkapitalisierung:
$193.99B
Einnahmen:
$42.88B
Nettoeinkommen (Verlust:
$6.34B
KGV:
31.11
EPS:
16.53
Netto-Cashflow:
$7.27B
1W Leistung:
-0.46%
1M Leistung:
-5.69%
6M Leistung:
-16.86%
1J Leistung:
-14.22%
1-Tages-Spanne:
$509.40
$526.76
1-Wochen-Bereich:
$509.40
$536.21
52-Wochen-Spanne:
$493.30
$627.88
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Firmenname
Thermo Fisher Scientific Inc
Sektor
Branche
Telefon
(781) 622-1000
Adresse
168 THIRD AVENUE, WALTHAM, MA
Vergleichen Sie TMO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
514.20 | 193.99B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
205.61 | 146.95B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
426.69 | 34.70B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
121.03 | 34.51B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
183.48 | 32.35B | 15.41B | 1.37B | 2.11B | 7.50 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-12-23 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-10-01 | Eingeleitet | Stephens | Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-03-18 | Fortgesetzt | Citigroup | Neutral |
| 2024-01-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-01-08 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-10-26 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-10-25 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-09-06 | Fortgesetzt | Citigroup | Buy |
| 2023-07-19 | Eingeleitet | Raymond James | Outperform |
| 2023-07-19 | Bestätigt | Robert W. Baird | Outperform |
| 2023-07-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2023-04-04 | Bestätigt | Barclays | Overweight |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-10-27 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-04-25 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2022-01-26 | Fortgesetzt | Barclays | Overweight |
| 2021-10-20 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-16 | Eingeleitet | The Benchmark Company | Buy |
| 2021-03-18 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-03 | Eingeleitet | Barclays | Overweight |
| 2021-01-08 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-02 | Eingeleitet | Goldman | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-14 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-08-20 | Fortgesetzt | JP Morgan | Overweight |
| 2020-07-15 | Hochstufung | Cleveland Research | Neutral → Buy |
| 2020-07-07 | Bestätigt | Needham | Buy |
| 2020-04-23 | Bestätigt | Needham | Buy |
| 2020-01-31 | Bestätigt | Needham | Buy |
| 2020-01-22 | Eingeleitet | Credit Suisse | Neutral |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-07-25 | Bestätigt | Needham | Buy |
| 2019-07-16 | Herabstufung | Needham | Strong Buy → Buy |
| 2019-05-30 | Eingeleitet | Wolfe Research | Outperform |
| 2019-05-23 | Bestätigt | Needham | Strong Buy |
| 2019-04-22 | Bestätigt | Needham | Strong Buy |
| 2019-04-16 | Bestätigt | BofA/Merrill | Buy |
Alle ansehen
Thermo Fisher Scientific Inc Aktie (TMO) Neueste Nachrichten
Breast Cancer Diagnostics Market Set for 6.9% CAGR Growth, projected to Hit USD 12.45 Billion by 2035 - GlobeNewswire Inc.
Thermo Fisher Scientific SVP sells $2.01 million in stock - Investing.com
Neurological Biomarkers: Global Market Review 2020-2024 and - GlobeNewswire
Molecular Breeding Market Insights, Competitive Intelligence and Growth Forecast 2025-2030 - GlobeNewswire Inc.
Mexico In-Vitro Diagnostics Market Deep Research 2025-2032 | Thermo Fisher Scientific Inc., Siemens Healthineers - openPR
Thermo Fisher Scientific: Not Living Up To Its Positioning (NYSE:TMO) - Seeking Alpha
WilmerHale Advises Thermo Fisher on its CHF 1.425 Billion Offering of Bonds - WilmerHale
Cas Nuclease Market Size, Forecast 2031 by Key Companies- Thermo - openPR
Insider Selling: Thermo Fisher Scientific Inc. (NYSE:TMO) CEO Sells $5,166,700.00 in Stock - Defense World
A New Era of STEMOptimization for Advanced Materials Discovery - AZoM
Lung Cancer Diagnostics Market Forecast Report and - GlobeNewswire
Lung Cancer Diagnostics Market Forecast Report and Competitive Analysis 2025-2033 Featuring llumina, Abbott, Thermo Fisher Scientific, QIAGEN, Roche, Sanofi, Agilent Technologies, bioMerieux - Yahoo Finance
Unit Dose Manufacturing Industry Report 2025-2030: Market - GlobeNewswire
Unit Dose Manufacturing Industry Report 2025-2030: Market to Cross $150.6 Billion Led by Catalent, Unither Pharmaceuticals, and Thermo Fisher Scientific - Yahoo Finance
Layoff Tracker: Atea Pharmaceuticals Cuts 25% of Workforce - BioSpace
Thermo Fisher Scientific: Strong Q4, Strategic M&A, And Poised For Growth In Life Sciences - Seeking Alpha
Thermo Fisher Scientific CEO sells $9.3 million in stock By Investing.com - Investing.com South Africa
Thermo Fisher Scientific CEO sells $9.3 million in stock - Investing.com India
Here’s Why Thermo Fisher Scientific (TMO) Fell in Q4 - MSN
Deutsche Bank Adjusts Price Target on Thermo Fisher Scientific to $615 From $630, Keeps Buy Rating - Marketscreener.com
Multiplex Assay Market Generated Opportunities, Future Scope - openPR
Thermo Fisher Scientific Inc. stock rises Wednesday, outperforms market - MarketWatch
Ryan Snyder On AI And Digital Innovation At Thermo Fisher Scientific - Forbes
Invest with Confidence: Intrinsic Value Unveiled of Thermo Fisher Scientific Inc - Yahoo Finance
Thermo Fisher Scientific EVP Michael Shafer sells $945,037 in stock - Investing.com
Thermo Fisher Scientific EVP Michael Shafer sells $945,037 in stock By Investing.com - Investing.com UK
Thermo Fisher Scientific Inc. (TMO): A Bull Case Theory - Insider Monkey
Assessment of the $1.41 Billion Peptide Synthesis Industry - GlobeNewswire
Assessment of the $1.41 Billion Peptide Synthesis Industry 2025-2029: Dominated by Bachem, Thermo Fisher Scientific, Merck, GenScript, and CEM Corporation - Yahoo Finance
Global Microbiological Testing of Water Market to Reach $2.3 Billion by 2027, Dominated by Tech Giants 3M - EIN News
Global Microbiological Testing of Water Market to Reach - GlobeNewswire
Citigroup Adjusts Price Target on Thermo Fisher Scientific to $570 From $650, Maintains Neutral Rating - Marketscreener.com
Ultrasonic Aspirator Market Detailed In New Research Report - openPR
February M&A deals: Thermo Fisher, Novartis, and CyberArk Software - The Business Journals
Is Thermo Fisher Scientific Stock Underperforming the S&P 500? - Nasdaq
High-Throughput Screening Technology Analysis and Global - GlobeNewswire
Is Thermo Fisher Scientific Stock Underperforming The S&P 500? - Barchart
US-based Thermo Fisher Scientific to expand India manufacturing base: Ashwini Vaishnaw - MSN
Thermo Fisher Scientific to Acquire Purification and Filtration Business - MedTech Intelligence
Thermo Fisher Expands Horizons with Bold $4.1 Billion Acquisition - Clinique Bio
Thermo Fisher (TMO): Among the Best Affordable Dividend Stocks to Buy According to Hedge Funds - Insider Monkey
Thermo Fisher Scientific Agreed to Acquire Solventum’s Purification and Filtration Business - Genetic Engineering & Biotechnology News
Microplastic Detection Market Report 2025, with Key Player Profiles for Thermo Fisher Scientific, Agilent Technologies, Bruker, JEOL and PerkinElmerResearchAndMarkets.com | FinancialContent Business Page - Financial Content
Rx Rundown: Thermo Fisher Scientific, the CDC, Eli Lilly and more - MM+M Online
Biotechnology company Thermo Fisher Scientific buys Solventum’s filtration and purification business for $4.1 billion - BioProcess Insider
Cell Culture Market Is Booming So Rapidly: Cell Culture Company, LLC, Thermo Fisher Scientific Inc. - openPR
Custom Antibody Service Market Growth in Future Scope 2025-2032 - openPR
Thermo Fisher Scientific, Inc. to Host Earnings Call - ACCESS Newswire
Thermo Fisher Scientific Inc. stock falls Thursday, underperforms market - MarketWatch
Spatial Imaging System | Thermo Fisher Scientific Inc. | Products - Photonics.com
Thermo Fisher Scientific: $4.1 Billion Deal For Solventum’s Purification And Filtration Business - Pulse 2.0
Finanzdaten der Thermo Fisher Scientific Inc-Aktie (TMO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.19%
2.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):